Digital Health Solution Market Access GERMANY - Join our DiGA Assessment Workshop

There are several options for market entry, reimbursement, and scaling within the German healthcare market, including selective contracts with public and private health insurers, direct B2B or B2B2C sales, private billing, and research and development or funding projects and DiGA.

Germany's DiGA (Digital Health Applications) pathway has become one of the most asked for and attractive reimbursement models for digital health innovations. By enabling physicians to prescribe digital health applications that are reimbursed by statutory health insurance, DiGA offers companies a unique opportunity to enter one of Europe's largest healthcare markets.

In this workshop, we will take a deep dive into the DiGA pathway and also briefly explore other market entry and scaling options.

For many digital health companies, the benefits of DiGA are compelling:

• Access to Germany's statutory health insurance system
• Prescription-based reimbursement
• Increased credibility among healthcare professionals and patients
• A structured pathway to market access and scaling

However, while DiGA is an attractive opportunity, it is not automatically the right strategy for every digital health solution.

Successfully entering DiGA requires much more than an innovative product. Companies need regulatory readiness, a clearly defined patient population, clinical evidence, a viable reimbursement strategy, and a realistic business case. Making this assessment early can save significant time, costs, and resources.

Join our workshop led by NG Cooperation to learn more about:

1. Fundamental Product Fit & Regulatory Requirements
Understand the basic DiGA eligibility criteria and the key requirements of the Digital Health Applications Regulation (DiGAV), including MDR, data protection, interoperability, and technical readiness.

2. Target Group Analysis
Identify the right patient population, prescribing physicians, and relevant healthcare stakeholders to assess your product's market fit.

3. Evidence & RCT Feasibility
Learn how to evaluate your existing clinical evidence, identify gaps, and determine whether a randomized controlled trial (RCT) or other study design is feasible.

4. Cost-Benefit Analysis
Estimate the investment required for the DiGA Fast Track, evaluate reimbursement potential, and determine whether pursuing DiGA is economically worthwhile.

5. Alternatives to the DiGA pathway

Explore alternative market entry and scaling options within the German healthcare market.